BioPharma Dive November 29, 2022
The drugmaker will no longer market the immunotherapy in the U.S. for urothelial carcinoma, the indication for which the drug was first approved.
Roche will withdraw its cancer immunotherapy Tecentriq for a type of bladder cancer in the U.S., the company announced Tuesday, completing a sweep of the drug’s accelerated approvals that have not been confirmed through further study.
The Swiss drugmaker will no longer market the drug for any form of urothelial carcinoma, the first setting for which Tecentriq gained approval more than six years ago. Roche previously narrowed Tecentriq’s label to cover only patients who couldn’t take chemotherapy or whose tumors express a protein that Tecentriq targets, after clinical trial results called into question whether Tecentriq helped patients...
Today's Sponsors
Today's Sponsor